baber/WOPTO huggingface dataset:
Patent NZ-554343-A (NZ)
Title: Method of preparing modified diallyl-N, N-disubstituted ammonium halide polymers
Inventor: SHING JANE WONG B
IPC: C08F4/00
Filed: 2005-10-15
Abstract: Disclosed is a method of preparing a modified diallyl-N,N-disubstituted ammonium halide polymer having a cationic charge of about 20 to about 80 mole percent, a RSV of from about 0.2 to about 12 dL/g, a charge density of less than about 7 milliequivalents/g polymer, and a number average particle size diameter of at least 1,000 nm comprising: (a) preparing an aqueous solution comprising one or more acrylamide monomers, one or more diallyl-N,N-disubstituted ammonium halide monomers, about 0.1 to less than about 3,000 ppm based on monomer of one or more chain transfer agents (such as sodium formate or sodium hypophosphite), and about 1 to about 1,000 ppm based on monomer of one or more cross-linking agents (such as N,N-methylenebisacrylamide); (b) initiating polymerization of the monomers; and (c) allowing the polymerization to proceed to the desired endpoint, wherein said chain transfer agents and cross-linking agents are added all at once prior to initiation of polymerization. Also disclosed is a method of increasing retention and drainage in a papermaking furnish comprising adding to the furnish an effective amount of a modified diallyl-N,N-disubstituted ammonium halide polymer prepared according to the method defined above and an effective amount of one or more high molecular weight, water-soluble cationic, anionic, nonionic, zwitterionic or amphoteric polymer flocculants.
Patent NZ-563862-A (NZ)
Title: Locking mechanism for a ladder
Inventor: ERIKSSON PER-OLOF
IPC: E06C1/12
Filed: 2006-05-29
Abstract: A locking mechanism for a collapsible ladder (1) comprising several ladder sections (5), each ladder section comprising two ladder bars (2, 3) arranged parallel to each other and interconnected at one end by a rung to form a U-shaped ladder section, and where each ladder section is telescopically inserted into a lower ladder section to form a collapsible ladder, and where dampers (23) are provided at the lower end of the ladder bars and where the locking mechanism comprises retaining mechanisms (20, 41) provided on each ladder bar, where a single pair of actuators of the locking mechanism can be arranged on any of the ladder sections and still be able to collapse the entire ladder.
Patent NZ-579886-A (NZ)
Title: Rainwater collection system employing low profile roof arched over land
Inventor: RAFFAELE PETER ROBERT
IPC: E03B1/02
Filed: 2008-02-25
Abstract: A rainwater collection system (10) including tension members (2) drawn tight over an arched strip or parcel of land (11). The tension members are pulled tight between stay means (3). Batons (4) are attached to the tension members which are then clad with roof sheeting means.
Patent NZ-585074-A (NZ)
Title: Refrigerator with an atomization device and a protection unit to supprss current flow to the user
Inventor: MORI KIYOSHI
IPC: A23L3/375
Filed: 2008-11-05
Abstract: A refrigerator is disclosed comprising a storage compartment (207) that is separated and heat-insulated from another area and an atomization device (215) including an electrode unit (222, 223) for spraying mist into the storage compartment (207). A protection unit is configured to suppress current flowing from the electrode unit (222, 223) to a user. The protection unit includes a case (225) accommodating the electrode unit (222, 223) with an opening through which the mist is sprayed by the atomization unit. The opening is sized to not allow a user's finger to pass. The protection unit further includes a current-limit circuit (231) to limit current discharged to a user via the atomization unit (215).
Patent NZ-590434-A (NZ)
Title: Domestic appliance, especially a dishwasher or washer
Inventor: ROSENBAUER MICHAEL
IPC: A47L15/00
Filed: 2009-07-23
Abstract: 590434 Disclosed is a domestic appliance (8). The appliance (8) has a control device (13) for controlling device components of the domestic appliance (8) during the execution of a program (I, III, III). At least one switching means (3, 5) partly de-energises the control device (13) after the program (I, II, III) has finished executing. The control device (13) has at least a first group of modules (21) and a second group of modules (23). The first group (21) controls the domestic appliance (8) before the beginning and/or after the end of the program (I, II, III) execution and the second group (23) controls the domestic appliance (8) while the program (I, II, III) is executing. A delay element (33) activates at least one of the switching means (3, 5) and de-energises after a predetermined period of time has elapsed. At least one of the switching means (3, 5) de-energises the second group of modules (23).
Patent NZ-592977-A (NZ)
Title: IgE CH3 PEPTIDE VACCINE
Inventor: BROWN ALAN DANIEL
IPC: A61K39/00
Filed: 2009-12-04
Abstract: 592977 Provided is an immunogen comprising at least one antigenic IgE peptide linked to an immunogenic carrier, wherein said antigenic IgE peptide consists of a specified amino acid sequence or an antigenic fragment thereof. The immunogenic carrier can be a virus-like particle, e.g. HBcAg, HBsAg or Qbeta VLP. Further immunogens can be added to the composition and formulated as a vaccine with an adjuvant.
Patent NZ-596991-A (NZ)
Title: Lens delivery system
Inventor: DOWNER DAVID ANTHONY
IPC: A61F2/16
Filed: 2010-06-04
Abstract: 596991 An intraocular lens delivery system includes an injector body (102) having a bore surrounded by an inner wall (104). The system further includes a plunger (200) configured to fit within the bore. A plurality of deflectable members (204) are connected to the plunger and configured to contact the inner wall (104) when the plunger (200) is inserted within the bore. The deflectable members centre the shaft (202) and, when inserted within the injector body, contribute to producing a predetermined force resisting advancement of the plunger. A method of manufacturing the delivery system is also disclosed.
Patent NZ-598598-A (NZ)
Title: Detection of aad-1 event das-40278-9
Inventor: CUI YUNXING CORY
IPC: C12P19/34
Filed: 2010-08-18
Abstract: Disclosed is a method for determining zygosity of a com plant comprising AAD-l com event DAS-40278-9, said event comprising the nucleotide sequence of SEQ ID NO: 1, wherein SEQ ID NO: 1 comprises a trans gene construct comprising an AAD-l gene, said transgene construct being flanked by a 5’ flanking com genomic DNA and a 3’ flanking com genomic DNA, said method comprising: obtaining a DNA sample of genomic DNA from said com plant; producing a contacted sample by contacting said DNA sample with a. a first event primer and a second event primer, wherein said first event primer specifically binds said transgene construct, said second event primer specifically binds said 5’ com genomic flanking DNA or said 3’ com genomic flanking DNA, and wherein said first event primer and said second event primer produce an event amplicon when subjected to TAQMAN PCR conditions b. a reference forward primer and a reference reverse primer that produce a reference amplicon from an endogenous com reference gene when subjected to TAQMAN PCR conditions c. a florescent event probe that hybridizes with said event amplicon d. a florescent reference probe that hybridizes with said reference amplicon; subjecting said contacted sample to fluorescence-based endpoint TAQMAN PCR conditions; quantitating said florescent event probe that hybridized to said event amplicon; quantitating said florescent reference probe that hybridized to said reference amplicon; comparing amounts of hybridized florescent event probe to hybridized florescent reference probe; and determining zygosity of DAS-40278-9 by comparing florescence ratios of hybridized fluorescent event probe and hybridized fluorescent reference probe.
Patent NZ-599049-A (NZ)
Title: Antagonists of dsg2 for treatment of cancer
Inventor: CHEN MIN-CHE
IPC: A61K38/17
Filed: 2010-09-22
Abstract: 599049 Disclosed is a monoclonal antibody as an antagonist for use as a medicament for preventing or treating cancer, wherein the monoclonal antibody specifically binds to the amino acid sequence: TQDVFVGSVEELSAAHTLVMKINATDADEPNTLNSKISYR, KINATDADEPNTLNSKISYR or EELSAAHTLV of the non-cell adhesion recognition (CAR) sites region of the EC2 domain of Dsg2 and inhibits epithelial mesenchymal transition (EMT).
Patent NZ-599343-A (NZ)
Title: Substituted piperidines that increase p53 activity and the uses thereof
Inventor: BOGEN STEPHANE L
IPC: A61K31/445
Filed: 2010-10-05
Abstract: Disclosed herein is a compound of Formula (1) as described herein or a pharmaceutically acceptable salt thereof. The compounds are useful as inhibitors of the Human Double Minute 2 (HDM2) protein. Also disclosed are pharmaceutical compositions comprising the above compounds and methods of treating cancer using the same. In one embodiment the compound is 3-(4-hydroxy-4-(2-methoxyphenyl)-1-((2R,3S)-2-propyl-1-(3-(trifluoromethyl)picolinoyl)-3-(5-(trifluoromethyl)thiophen-3-yloxy)piperidine-3-carbonyl)piperidin-2-yl)propanoic acid.
Patent NZ-600306-A (NZ)
Title: Salty taste enhancing agent that contains an ezymatic decomposition product of an animal and an enzymatic product of an plant protein and food or drink containing the same
Inventor: SHIMONO MASASHI
IPC: A23L17/00
Filed: 2009-03-23
Abstract: Disclosed is a salty taste enhancer that contains an enzymatic decomposition product of an animal protein derived from fish or shellfish and a deamidated enzymatic decomposition product of a plant protein obtained by processing beans, wheat, corn or rice at a ratio of between 1:10 and 10:1,wherein the enzymatic decomposition products are treated with a protein-hydrolyzing enzyme.
Patent NZ-601338-A (NZ)
Title: Concrete mixer truck having a mixer drum capable of carrying freshly mixed concrete
Inventor: SHIMIZU HIROYUKI
IPC: B28C5/42
Filed: 2012-07-18
Abstract: Disclosed is a concrete mixer truck having a mixer drum capable of carrying freshly mixed concrete. The mixer truck includes a driving device that is driven by rotation of an engine so as to drive the mixer drum to rotate using a fluid pressure of a working fluid. A pressure detector detects a pressure of the working fluid in the driving device and a controller has a material introduction determination unit that determines whether or not the freshly mixed concrete has been introduced into the mixer drum. A pressure determination unit determines whether or not the pressure of the working fluid detected by the pressure detector has fallen to a set pressure set in advance in accordance with a carrying amount and a fluidity of the freshly mixed concrete after the introduction of the materials for the freshly mixed concrete into the mixer drum. A notification device notifies an operator that the pressure of the working fluid in the driving device has fallen to the set pressure on the basis of the determination made by the pressure determination unit.
Patent NZ-603996-A (NZ)
Title: Cells or cell lines that stably express a bitter taste receptor and methods of making them
Inventor: SHEKDAR KAMBIZ
IPC: C12N5/00
Filed: 2010-02-01
Abstract: 603996 Disclosed is a method of producing a cell line stably expressing a bitter receptor, comprising: a. introducing a nucleic acid encoding the bitter receptor into a plurality of cells; b. introducing a molecular beacon that detects expression of the bitter receptor into the plurality of cells provided in step (a); c. isolating a cell that expresses the bitter receptor; and d. generating a cell line from the cell isolated in step (c); wherein said generated cell line produces Z’ value of at least 0.45 in a G protein mediated cell-based assay or a calcium flux cell-based assay. Further disclosed is an isolated cell or cell line that stably expresses a bitter receptor, wherein said bitter receptor is expressed from a nucleic acid introduced into the cell or cell line, wherein said cell or cell line does not endogenously express the bitter receptor, and wherein said cell or cell line is capable of producing a Z’ value of at least 0.45 in a G protein mediated cell-based assay or a calcium flux cell-based assay. Further disclosed is an isolated cell or cell line that stably expresses a bitter receptor, wherein the bitter receptor is expressed from an endogenous nucleic acid by engineered gene activation, and wherein said cell or cell line is capable of producing a Z’ value of at least 0.45 in a G protein mediated cell-based assay or a calcium flux cell-based assay.
Patent NZ-604891-A (NZ)
Title: Combination of glyt1 compound with antipsychotics
Inventor: ALBERATI DANIELA
IPC: A61K31/497
Filed: 2011-08-05
Abstract: Disclosed is a pharmaceutical combination comprising an atypical antipsychotic drug and a glycine transporter inhibitor GlyT1 receptor antagonist of formula (I). An examples of a compound of formula (I) is [4-(3-fluoro-5-trifluoromethylpyridin-2-yl)-piperazin-1-yl]-[5-methanesulfonyl-2-(2,2,2-trifluoro-1-methyl-ethoxy)-phenyl]-methanone (also known as Bitopertin or RG1678). Examples of an atypical antipsychotic drug are risperidone, paliperidone, olanzapine, aripiprazole, quetiapine and ziprasidone. The compounds are useful in the treatment of positive and negative symptoms in schizophrenia.
Patent NZ-605674-A (NZ)
Title: X-ray imaging at low contrast agent concentrations and/or low dose radiation
Inventor: KAISER CLEMENS
IPC: A61K49/04
Filed: 2011-07-12
Abstract: Disclosed herein is X-ray examinations and the improvement of patient safety during such. More specifically, disclosed are X-ray diagnostic compositions having ultra-low concentrations of iodine. Further disclosed are methods of X-ray examinations wherein a body is administered with an X-ray diagnostic composition and irradiated with a reduced radiation dose. In one embodiment, the iodinated X-ray contrast agent is iodixanol or the compound of formula II.
Patent NZ-610389-A (NZ)
Title: Use of a composition comprising an antimicrobial peptide as a food preservative
Inventor: CARREIRA ALEXANDRA MANUELA LOURENÇO
IPC: A23B7/154
Filed: 2011-10-12
Abstract: 610389 Disclosed is the use of a composition comprising an antimicrobial polypeptide comprising the Blad sequence shown in RRQRNPYHFSSQRFQTLYKNRNGKIRVLERFDQRTNRLENLQNYRIVEFQSKPNTLILPKHSDADYVLVVLNGRATITIVNPDRRQAYNLEYGDALRIPAGSTSYILNPDDNQKLRVVKLAIPINNPGYFYDFYPSSTKDQQSYFSGFSRNTLEATFNTRYEEIQRIILGNED (SEQ ID NO:4) or an active variant thereof to prevent or inhibit spoilage of a foodstuff by a microorganism, wherein said active variant has antimicrobial activity and comprises a sequence which has at least 70% identity to SEQ ID NO:4 or to a fragment of SEQ ID NO:4 which is at least 60 amino acids in length.
Patent NZ-615126-A (NZ)
Title: Processes to make water and oil repellent bcf yarn
Inventor: TUNG WAE-HAI
IPC: D06M15/576
Filed: 2012-03-15
Abstract: Disclosed are processes for applying anti-soil compositions onto BCF yarns during cable or air twisting processes prior to weaving, knitting or tufting into finished carpet. The process foregoes the need for downstream environmentally unfavorable dyeing and low pH chemical treatment processes on the finished carpet. The anti-soil composition can be comprised of a high specific surface energy chemical or other material, for example a fluorochemical. Further, the anti-soil composition can further comprise an anti-stain component. Also disclosed are systems, BCF yarns, and carpets made from the BCF yarn treated by the disclosed process.
Patent NZ-616804-A (NZ)
Title: Vaccine delivery method
Inventor: HARN DONALD A
IPC: A61P33/12
Filed: 2012-04-18
Abstract: Disclosed is a composition comprising: -a self assembling peptide that forms a stable hydrogel at physiological salt concentrations; -an adjuvant, wherein the adjuvant comprises a Toll-Like Receptor (TLR) agonist; and -one or more antigens. Also disclosed is the use of the above-described composition in the manufacture of a medicament for immunising a subject.
Patent NZ-619883-A (NZ)
Title: Methods and compositions for diagnosis and prognosis of renal injury and renal failure
Inventor: MCPHERSON PAUL
IPC: G01N33/68
Filed: 2010-09-21
Abstract: A method for evaluating renal status in a subject and a kit when used in the method are disclosed. The method comprises performing a plurality of assays configured to detect both of the proteins soluble oxidized low-density lipoprotein receptor 1 and neutrophil elastase in one or more body fluid samples obtained previously from the subject by contacting the body fluid sample(s) with molecules that bind to each of soluble oxidized low-density lipoprotein receptor 1 and neutrophil elastase under conditions sufficient for such binding to occur. A measured concentration is determined of each of soluble oxidized low-density lipoprotein receptor 1 and neutrophil elastase from the amounts of the molecules bound thereto in the body fluid samples. The measured concentration of each of soluble oxidized low-density lipoprotein receptor 1 and neutrophil elastase are combined using a function that converts the assay results into a single composite result to thereby provide a combined concentration of soluble oxidized low-density lipoprotein receptor 1 and neutrophil elastase for the subject. The combined concentration of soluble oxidized low-density lipoprotein receptor 1 and neutrophil elastase is compared to a threshold combined concentration; and the assay results are correlated to the renal status of the subject. The correlating comprises (i) assigning a diagnosis that reduced or worsening renal function or an event an event associated with reduced or worsening renal function has occurred, or assigning a risk or likelihood that reduced or worsening renal function or an event an event associated with reduced or worsening renal function is likely to occur in future, when the combined concentration of soluble oxidized low-density lipoprotein receptor 1 and neutrophil elastase is above the threshold concentration; or (ii) assigning a diagnosis that reduced or worsening renal function or an event an event associated with reduced or worsening renal function has not occurred, or assigning a risk or likelihood that reduced or worsening renal function or an event an event associated with reduced or worsening renal function is not likely to occur in future, when the combined concentration of soluble oxidized low-density lipoprotein receptor 1 and neutrophil elastase is below the threshold concentration. Also disclosed is a combined use of antibodies or antibody fragments in a method performed ex vivo on one or more body fluid samples obtained previously from a subject in determining a present or future reduced renal function in the subject, wherein the antibodies or antibody fragments bind independently to (i) neutrophil elastase or an epitope thereof ;and (ii) soluble oxidized low-density lipoprotein receptor 1 or anepitope thereof.
Patent NZ-620991-A (NZ)
Title: Isobutanol compositions for fuel blending and methods for the production thereof
Inventor: WOLF LESLIE R
IPC: C10L1/04
Filed: 2012-08-17
Abstract: The disclosure relates to isobutanol compositions for fuel blending and associated fuel blends. The composition contains isobutanol, optionally, an octane improving component and a vapour pressure adjustment component. The vapour pressure adjustment component may be n-butane, isomerate or natural gasoline. the octane improving component may be toluene or heavy reformate. The composition may further comprise a driveability component. The compositions, when blended with gasoline, improve driveability (e.g. cold start and warm up) over gasoline blended with isobutanol alone.
Patent NZ-705128-A (NZ)
Title: Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
Inventor: CHEN FRANCINE ZHIFEN
IPC: C07K16/00
Filed: 2011-03-01
Abstract: Disclosed is a B7-H3 binding molecule (PRCA157), wherein the molecule is an isolated antibody, an immunoreactive fragment thereof, or a diabody which comprises a variable domain that specifically binds an extracellular domain of B7-H3, wherein said molecule: (a) binds to 4Ig and 2Ig isoforms of B7-H3 that is endogenously expressed on the surface of a cancer cell and (b) comprises the CDR sequences of RASESIYSYLA, NTKTLPE, QHHYGTPPW, SYGMS, VATINSGGSNTYYPDSLKG and HDGGAMDY
Patent NZ-708447-A (NZ)
Title: Adhesive tape dispenser and an adhesive tape roll
Inventor: BRUSIUS DANIEL
IPC: B65H35/07
Filed: 2015-05-25
Abstract: Conventional tape dispensers generate a large amount of noise when tape is applied to an object, this causes irritation to the end user. In order to reduce the noise, the device comprising a swivel arm pivotably mounted about a rotational axis to the carrier unit support member which is arranged and adjusted to support the adhesive tape roll by pressing against said support member via the swivel arm being impacted by a spring element. This reduces the noise generated during the unwinding process of a tape from an adhesive tape dispenser.
Patent NZ-710495-A (NZ)
Title: Therapeutic compositions and methods involving mrna transfection
Inventor: HERZBERG MARK C
IPC: C12P19/34
Filed: 2014-01-10
Abstract: This disclosure describes compositions and methods involved in tumor suppression and inhibiting infection of cells by pathogens. Generally, the compositions include an mRNA cargo that can provide a therapeutic benefit after being introduced into an epithelial cell via topical administration. In some cases, the mRNA can encode a polypeptide. In some cases, the polypeptide can suppress epithelial cell proliferation. In other embodiments, the polypeptide can be involved in innate immunity. In various embodiments, the polypeptide can include cathelicin antimicrobial protein (CAMP), calprotectin, S100A8, S100A9, a β-defensin, S100A7, secretory leukocyte inhibitor, lipocalin 2, or lysozyme. In some embodiments, the mRNA can include a stabilizing moiety such as, for example, a 5’ cap or a 3’ extension.
Patent NZ-724063-A (NZ)
Title: Pyrazine derivatives having pharmaceutical activity
Inventor: BERGLUND SUSANNE ELISABETH
IPC: C07D401/06
Filed: 2015-03-17
Abstract: The present invention provides a compound of a formula (I): or a pharmaceutically acceptable salt thereof; a process for preparing such a compound; and to the use of such a compound in the treatment of an ENaC mediated disease state (such as asthma, CF or COPD).
Patent NZ-726052-A (NZ)
Title: Phosphatidylinositol 3-kinase inhibitors
Inventor: PHILLIPS BARTON
IPC: C07D513/04
Filed: 2015-06-10
Abstract: The present application provides the compounds of formula (J), or pharmaceutically acceptable salts, isomers, or a mixture thereof, wherein n, m, q, A’, W1, W2, W3, R1, R2, and R3 are described herein. The compounds are inhibitors to the activities of phosphatidylinositol 3-kinase (PI3K) and are useful for treating conditions mediated by one or more PI3K isoforms. The present application further provides pharmaceutical compositions that include a compound of formula (J), or pharmaceutically acceptable salts, isomers, tautomer, or mixture thereof, and methods of using these compounds and compositions for treating conditions mediated by one or more PI3K isoforms.